Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The 23rd International Myeloma Society (IMS) Annual Meeting was held in Glasgow, Scotland, from September 23-26, 2026. The meeting brought together leading experts to discuss the latest clinical and experimental advances in multiple myeloma.

IMS 2026

The 23rd International Myeloma Society Annual Meeting
23–26 September 2026 | Glasgow, Scotland

IMS 2026

The 23rd International Myeloma Society Annual Meeting
23–26 September 2026 | Glasgow, Scotland
The 23rd International Myeloma Society (IMS) Annual Meeting was held in Glasgow, Scotland, from September 23-26, 2026. The meeting brought together leading experts to discuss the latest clinical and experimental advances in multiple myeloma.
View all videos

Latest Videos

View all videos
0:47
Insights into the most anticipated changes in myeloma imaging over the next 5 years
Jens Hillengass • 23 Sep 2026
1:46
Hypogammaglobulinemia, infection risk, and IgG replacement therapy in myeloma
Wolfgang Willenbacher • 25 Sep 2026
1:17
Individualized bridging therapy before BCMA-directed CAR T-cell therapy
Jule Cecilia Artzenroth • 24 Sep 2026
2:49
Efficacy and safety of GPRC5D-targeted QLS32015 in multiple myeloma
Jian Cui • 23 Sep 2026

Trial Updates

View all
2:49
Efficacy and safety of GPRC5D-targeted QLS32015 in multiple myeloma
Jian Cui • 23 Sep 2026
1:35
Ramantamig safety and efficacy in relapsed/refractory multiple myeloma
Jeffrey Matous • 25 Sep 2026

Immuno-Oncology

View all
1:46
Hypogammaglobulinemia, infection risk, and IgG replacement therapy in myeloma
Wolfgang Willenbacher • 25 Sep 2026
1:17
Individualized bridging therapy before BCMA-directed CAR T-cell therapy
Jule Cecilia Artzenroth • 24 Sep 2026

MRD

View all
0:47
Insights into the most anticipated changes in myeloma imaging over the next 5 years
Jens Hillengass • 23 Sep 2026
6:22
CAMMA 1: fixed-duration cevostamab shows durable responses in R/R multiple myeloma
Ravi Vij • 15 Oct 2026

Disease Biology

View all
7:31
APRIL depletion and loss of durable antibody-mediated immunity in multiple myeloma
Noé Perron • 24 Sep 2026
2:39
Genomic and immune signatures of ibrutinib response & resistance in Waldenström’s macroglobulinemia
Tina Bagratuni • 23 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals